Identification of Fibrinogen as a Plasma Protein Binding Partner for Lecanemab Biosimilar IgG: Implications for Alzheimer's Disease Therapy
Jean‐Pierre Bellier, Andrea M. Román Viera, Caitlyn Christiano, Juliana A. U. Anzai, Stephanie Moreno, Emily C. Campbell, Lucas Godwin, Amy Li, Alan Y. Chen, Sarah Alam, Adriana Saba, Han bin Yoo, Hyun‐Sik Yang, Jasmeer P. Chhatwal, Dennis J. Selkoe, Lei Liu
This study identifies fibrinogen as a plasma protein binding partner for lecanemab biosimilar, suggesting it may affect drug half-life and free antibody levels in Alzheimer's disease therapy.
bioRxiv · May 1, 2024 · PreprintNeuroscience